Aripiprazole: A treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome

Djebara, Mouna Ben; Worbe, Yulia; Schüpbach, Michaël; Hartmann, Andréas

doi:10.1002/mds.21859

Cited by 22 publications

(17 citation statements)

References 14 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, this drug should be considered because of its promising perspective based on actual clinical experiences. Even in “refractory” TS, aripiprazole has shown about 75% reduction of severe coprolalia in a 28-year-old man [16] as well as good efficacy in treating TS and coexisting OCD in an adult female [283]. Accordingly, Budman et al [32] found in their retrospective, observational study of 37 children and adolescents with TS who were refractory to previous treatment that aripiprazole still reduced tics as well as explosive outbursts in these patients.…”

Section: Pharmacological Treatment Options For Tsmentioning

confidence: 99%

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment

Roessner¹,

Plessen²,

Rothenberger³

et al. 2011

Eur Child Adolesc Psychiatry

382

385

View full text Add to dashboard Cite

To develop a European guideline on pharmacologic treatment of Tourette syndrome (TS) the available literature was thoroughly screened and extensively discussed by a working group of the European Society for the Study of Tourette syndrome (ESSTS). Although there are many more studies on pharmacotherapy of TS than on behavioral treatment options, only a limited number of studies meets rigorous quality criteria. Therefore, we have devised a two-stage approach. First, we present the highest level of evidence by reporting the findings of existing Cochrane reviews in this field. Subsequently, we provide the first comprehensive overview of all reports on pharmacological treatment options for TS through a MEDLINE, PubMed, and EMBASE search for all studies that document the effect of pharmacological treatment of TS and other tic disorders between 1970 and November 2010. We present a summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice. This summary is, however, rather a status quo of a clinically helpful but merely low evidence guideline, mainly driven by expert experience and opinion, since rigorous experimental studies are scarce.

show abstract

Section: Pharmacological Treatment Options For Tsmentioning

confidence: 99%

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment

Roessner¹,

Plessen²,

Rothenberger³

et al. 2011

Eur Child Adolesc Psychiatry

382

385

View full text Add to dashboard Cite

show abstract

“…Aripiprazole has been reported to be less likely to cause weight gain in adults compared to other atypical neuroleptics (Kolotkin et al 2008). Recently, several case series and one openlabel study have reported on the use of aripiprazole in children and adolescents with TD or chronic tic disorder, but to date, no controlled trials have been reported (Hounie et al 2004;Dehning et al 2005;Kastrup et al 2005;Murphy et al 2005;Bubl et al 2006;Constant et al 2006;Davies et al 2006;Duane 2006;Fountoulakis et al 2006;Yoo et al 2006;Ben Djebara et al 2008;Budman et al 2008;Kawohl et al 2008;Seo et al 2008;Stenstrom and Sindo 2008;Winter et al 2008). These case reports and open-label series have suggested that aripiprazole at doses of 2.5-15 mg daily appears to reduce tic severity as judged by clinician rating scales.…”

Section: Introductionmentioning

confidence: 99%

Aripiprazole in Children and Adolescents with Tourette's Disorder: An Open-Label Safety and Tolerability Study

Lyon

Samar

Jummani

et al. 2009

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: The aim of this study was to conduct a prospective safety and tolerability study of aripiprazole for the treatment of tics in children and adolescents with Tourette's disorder (TD). Method: Eleven subjects (10 males) with TD (age 9-19 years, mean 13.36, standard deviation [SD] 3.33) who did not respond or were unable to tolerate previous tic medication were treated with aripiprazole in an open-label, flexible-dosing study over 10 weeks. Tic severity was rated using the Yale Global Tic Severity Scale (YGTSS) and the Clinical Global Impressions Scale for tics (CGI-Tics) at baseline and at follow-up. Results: The mean (AESD) daily dose for aripiprazole was 4.5 AE 3.0 mg. Mean (AESD) YGTSS Global Severity scores reduced from 61.82 AE 13.49 at baseline to 33.73 AE 15.18 at end point; mean YGTSS total tic scores reduced from 28.18 AE 7.74 at baseline to 16.73 AE 7.54 at end point. Mean (AESD) CGI-Tic severity scores reduced from 4.45 AE 0.52 (moderate-marked) at baseline to 3.18 AE 0.60 (mild) at end point. On the CGI-Tic improvement scale, 10 (

show abstract

“…It also has a high affinity with the serotonin receptor system, working as an antagonistic on 5-HT 2A receptors,95,96 and a partial agonistic on 5-HT 2C and 5-HT 1a receptors 97. Despite the lack of randomized double-blind and placebo-controlled studies, since 2004 more than 200 cases in at least 25 mostly open studies have been published, reporting good efficacy of aripiprazole in the treatment of tics for both adults and children 95,98–120. For instance, one larger retrospective study describes tic reduction in 29 of the 37 patients, who all tolerated the drug and continued the treatment 95.…”

Section: Resultsmentioning

confidence: 99%

Update on the role of antipsychotics in the treatment of Tourette syndrome

Huys¹,

Hardenacke²,

Poppe³

et al. 2012

NDT

View full text Add to dashboard Cite

Tourette syndrome (TS) is a neuropsychiatric disorder with typical onset in childhood and characterized by chronic occurrence of motor and vocal tics. The disorder can lead to serious impairments of both quality of life and psychosocial functioning, particularly for those individuals displaying complex tics. In such patients, drug treatment is recommended. The pathophysiology of TS is thought to involve a dysfunction of basal ganglia-related circuits and hyperactive dopaminergic innervations. Congruently, dopamine receptor antagonism of neuroleptics appears to be the most efficacious approach for pharmacological intervention. To assess the efficacy of the different neuroleptics available, a systematic, keyword-related search in PubMed (National Library of Medicine, Washington, DC) was undertaken. Much information on the use of antipsychotics in the treatment of TS is based on older data. Our objective was to give an update and therefore we focused on papers published in the last decade (between 2001 and 2011). Accordingly, the present review aims to summarize the current and evidence-based knowledge on the risk-benefit ratio of both first and second generation neuroleptics in TS.

show abstract

Aripiprazole: A treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome

Cited by 22 publications

References 14 publications

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment

Aripiprazole in Children and Adolescents with Tourette's Disorder: An Open-Label Safety and Tolerability Study

Update on the role of antipsychotics in the treatment of Tourette syndrome

Contact Info

Product

Resources

About